Workflow
ELYXYB®
icon
Search documents
Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI
Globenewswire· 2025-09-26 19:57
Core Viewpoint - Scilex Holding Company has completed the initial tranche of a $150 million investment in Datavault AI Inc., acquiring 15 million shares at an effective price of $0.5378 per share, with potential for additional shares pending stockholder approval [1]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [3][5]. - The company targets high unmet needs in the market with its non-opioid therapies, aiming to improve patient outcomes [3]. Commercial Products - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved for neuropathic pain relief [3]. - ELYXYB®, an FDA-approved oral solution for acute migraine treatment [3]. - Gloperba®, the first liquid oral version of colchicine for gout flare prophylaxis [3]. Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA), a viscous gel for epidural injections to treat sciatica, which has completed Phase 3 studies and received Fast Track status from the FDA [4]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completed a Phase 2 trial and has also received Fast Track status [4]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [4]. Investment Details - The initial tranche of the investment in Datavault AI Inc. involves the acquisition of 15 million shares, with the potential for up to 278,914,094 shares in total, subject to stockholder approval [1]. - The effective purchase price for the shares is $0.5378, with adjustments possible for stock splits [1].
Scilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI
Globenewswire· 2025-09-25 19:45
Core Viewpoint - Scilex Holding Company has announced a strategic investment of $150 million in Bitcoin in Datavault AI Inc. to support its growth in supercomputing infrastructure and data monetization [1][3]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [6][7]. - Datavault AI is positioned to leverage AI-driven analytics and blockchain technology to address challenges in data integrity and monetization across various industries, including biotech and energy [2][11]. Investment Details - The investment will provide Datavault with growth capital to expand its operations and unlock new revenue streams [1]. - Scilex is expected to receive up to 278,914,094 shares of Datavault common stock at an effective purchase price of $0.5378 per share, with specific terms regarding share issuance and board representation [4]. Market Potential - The global AI market is projected to reach $1.8 trillion by 2030, while the life sciences analytics market is estimated at $35.69 billion in 2024, growing at an 11.4% CAGR through 2030 [2]. - The biotech data monetization market is expected to reach a size of $30-50 billion by 2024, indicating significant growth potential for Scilex's investment strategy [3]. Strategic Alignment - Scilex aims to leverage its expertise in the biotech sector to guide Datavault in maximizing revenue generation while expanding its market presence [5]. - The collaboration is expected to create a marketplace for Real-World Assets (RWA) in the biotech and pharmaceutical industry, utilizing blockchain technology for ownership representation [3].
Scilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury Management
Globenewswire· 2025-09-24 14:11
Core Viewpoint - Scilex Holding Company has signed a non-binding Memorandum of Understanding (MOU) with Biconomy.com to explore future cryptocurrency and treasury management strategies, potentially involving over a billion dollars in digital assets [1][2]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [4][6]. - The company targets high unmet needs and large market opportunities with non-opioid therapies, aiming to improve patient outcomes [4]. Product Portfolio - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved for neuropathic pain relief [4]. - ELYXYB®, an FDA-approved oral solution for acute migraine treatment [4]. - Gloperba®, the first liquid oral version of colchicine for gout flare prophylaxis [4]. - The company has three product candidates in development: - SP-102 (SEMDEXA), a viscous gel for lumbosacral radicular pain, with a completed Phase 3 study and Fast Track status from the FDA [5]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completing a Phase 2 trial [5]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [5]. Strategic Collaboration - The MOU with Biconomy aims to establish a cryptocurrency treasury management strategy that balances security, liquidity, compliance, and yield [2]. - The collaboration is intended to create long-term value in Scilex's digital assets and support the transition to a crypto-powered economy [3].
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 2025
Globenewswire· 2025-09-23 10:00
Core Viewpoint - Semnur Pharmaceuticals has successfully completed its business combination with Denali Capital Acquisition Corp, transitioning to a public company to enhance growth and address non-opioid pain management needs [1][2][3] Company Overview - Semnur Pharmaceuticals, Inc. is a clinical late-stage specialty pharmaceutical company focused on developing and commercializing novel non-opioid pain therapies, particularly targeting moderate to severe chronic radicular pain/sciatica with its product candidate SP-102 (SEMDEXA™) [4][5] - The combined company will operate under the name Semnur Pharmaceuticals, Inc., with shares trading on the OTC Markets under the ticker symbols "SMNR" and "SMNRW" starting September 23, 2025 [2][7] Business Combination Details - The business combination was officially closed on September 22, 2025, allowing Semnur to access public capital markets for business growth [1][3] - Scilex Holding Company owns approximately 87.5% of Semnur's common stock post-business combination, indicating strong backing for the company's future endeavors [7] Leadership Statements - Henry Ji, Executive Chairperson of Semnur, emphasized the importance of public capital markets in enhancing business growth and fulfilling the company's mission [3] - Jaisim Shah, CEO of Semnur, expressed pride in the company's leadership in non-opioid therapeutics and the aim to accelerate access to these treatments through advancing clinical development and payer adoption [3] Product Development Focus - Semnur is advancing its second Phase 3 clinical development for SP-102, which is a novel gel formulation for epidural administration aimed at treating chronic radicular pain/sciatica [3][4] - The company is committed to increasing access to prescription non-opioid therapeutics and expanding its market presence [3]
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination
Globenewswire· 2025-09-22 19:49
Core Viewpoint - Scilex Holding Company announced the successful closing of a business combination with Denali Capital Acquisition Corp, resulting in the formation of Semnur Pharmaceuticals, Inc., which will focus on non-opioid pain management products [1][2][3] Company Overview - Scilex is dedicated to acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [1][5] - The company aims to address high unmet needs in the market with its innovative therapies [5] Business Combination Details - The combined entity will operate under the name Semnur Pharmaceuticals, Inc., with shares trading on the OTC Markets under the ticker symbols "SMNR" and "SMNRW" [2][6] - Scilex holds approximately 87.5% of Semnur's common stock post-business combination [6] Leadership Statements - Henry Ji, CEO of Scilex, emphasized the importance of public capital markets for business growth and fulfilling the mission of addressing non-opioid pain management needs [3] - Jaisim Shah, CEO of Semnur, expressed pride in leading the development of prescription non-opioid therapeutics and aims to accelerate access to these treatments [3] Product Pipeline - Semnur's lead product candidate, SP-102 (SEMDEXA), is a novel gel formulation for epidural administration targeting chronic radicular pain/sciatica [10] - Scilex has additional product candidates, including SP-103 and SP-104, targeting acute pain and fibromyalgia, respectively [8]
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule
Globenewswire· 2025-04-30 17:46
Core Viewpoint - Scilex Holding Company has regained compliance with Nasdaq's minimum closing bid price requirement, maintaining a minimum closing bid price of $1.00 per share for at least ten consecutive trading days as of April 30, 2025 [1] Company Overview - Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [3][5] - The company targets high unmet needs and large market opportunities with non-opioid therapies to improve patient outcomes [3] Commercial Products - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved for neuropathic pain relief associated with postherpetic neuralgia [3] - ELYXYB®, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [3] - Gloperba®, the first liquid oral version of colchicine for the prophylaxis of painful gout flares in adults [3] Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA), a viscous gel formulation for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [4] - SP-103, a next-generation formulation of ZTlido for acute pain, which has recently completed a Phase 2 trial and also received Fast Track status from the FDA [4] - SP-104, a low-dose delayed-release naltrexone hydrochloride for fibromyalgia treatment [4]